Navigation Links
Statement from the Consumer Healthcare Products Association on Today's Joint FDA Advisory Committee Recommendations Regarding Pediatric Over-the-Counter Cough and Cold Medicines
Date:10/19/2007

WASHINGTON, Oct. 19 /PRNewswire-USNewswire/ -- Following is a statement by Linda A. Suydam, D.P.A., president of the Consumer Healthcare Products Association (CHPA), regarding the recommendations issued today by the U.S. Food and Drug Administration's Nonprescription Drugs Advisory Committee and Pediatric Advisory Committee. At a meeting this week, the joint committee addressed the use of over-the-counter cough and cold medicines in children.

"For decades, parents and other caregivers have relied upon and trusted pediatric cough and cold medicines to relieve symptoms of the common cold in children and provide real comfort to children with runny noses, congestion and coughs.

"We believe that some of today's advisory committee recommendations support and confirm the risk-management efforts we have proposed. However, other recommendations -- notably the split vote to make single active ingredients no longer available for use in children under six years old -- if adopted by FDA, would unduly limit parents' access to medicines that work and are safe when taken as directed. The committee's split majority vote on this matter clearly did not reflect a consensus of opinion, and we hope the FDA will weigh this recommendation with great caution. Adoption of this recommendation would leave parents with no over-the-counter medicinal relief when their children are suffering from cold symptoms.

"The data clearly show that these medicines are very safe when used as directed and that harm to this age group, while very rare, is attributable in most cases to accidental ingestion -- an issue of safekeeping that is best addressed through education.

"Over-the-counter cough and cold medicines with multiple ingredients play an important role in relieving suffering from the common cold. It is easier and more practical to treat a child with a multiple symptom relief product. And the data presented at the advisory committee meeting show that multiple-ingredient products are as safe if not even less susceptible to misuse.

"Today, the advisory committee decided that there was insufficient evidence in pediatric populations to support efficacy. This is an issue we will address with FDA. We are already planning pharmacokinetic studies in children, which are the first step toward confirming correct dosing, and we will work with FDA to design appropriate pediatric clinical efficacy studies."

CHPA is the 126-year-old trade association representing U.S. manufacturers and distributors of over-the-counter medicines and nutritional supplement products.

http://www.chpa-info.org


'/>"/>
SOURCE Consumer Healthcare Products Association
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Paracetamol May Cause Live Damage Warns Consumer Education and Research Centre
2. Iodex goes to SmithKline Beecham consumer Healthcare
3. Consumer group seeks Sibutramine ban
4. Identifying What Consumers Look For On Food Stuff Labels
5. Consumers Becoming More Health Conscious Than Calorie Conscious
6. With More Appearance Conscious Consumers The Need For Slimming Products Is Rapidly Rising
7. Consumers of soft drinks to be more alert
8. Consumers Worried About Trans-Fats The Most
9. New Plastic Surgery Unit Set Up In Kolkata To Meet Ever-Increasing Consumer Demand
10. Health care system “Consumer friendly” by 207
11. Chocolate makers to be health wise and urge consumers to be too!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... “Who Would Have Dreamed: A Novel of Miracles”: ... woman who tried to understand its purpose in her life. “Who Would Have Dreamed: A ... powerful faith and a love of writing. , Sharon shares that she started ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... networking-technology company founded by patient survivors, today announced formation of its first ... technologies and patient-inspired initiatives. , Like HCP founders, the global advisory ...
(Date:1/24/2017)... IL (PRWEB) , ... January 23, 2017 , ... ... is partnering with Plug and Play, the world’s largest start-up platform headquartered in ... companies a year. , OSF Ventures recently signed a three-year agreement to ...
(Date:1/24/2017)... ... January 23, 2017 , ... The TouchPoint Solution, parent company ... metrics into the product’s app. The data replicates and validates Co-Founder and ... just 30 seconds of using Buzzies, people experienced a 74 percent reduction in ...
(Date:1/23/2017)... ... 2017 , ... A Northwestern Pennsylvania addiction treatment center unveiled ... Rehabilitation & Recovery Center’s new website can be found at AlpineSpringsRehab.com . ... and retooled website. The treatment center has also revamped its social media strategy, ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... , Jan. 23, 2017  HOPE BIOSCIENCES announced ... to develop and commercialize nuc -gemcitabine™ (APTA-12/HOPE-888) ... Korean pharmaceutical company. nuc -Gemcitabine ... against surface nucleolin found on many cancer cells, ... ADCs (antibody drug conjugates) or SMDCs (small molecule ...
(Date:1/23/2017)... ROCKVILLE, Md. , Jan. 23, 2017 /PRNewswire/ ... to advancing a new standard in respiratory care, ... Committee for Orphan Medicinal Products has granted Orphan ... the treatment of Bronchiolitis Obliterans Syndrome (BOS).  ... Drug Designation from the EMA to treat patients ...
(Date:1/23/2017)... Jan. 23, 2017  Based on its recent ... Sullivan recognizes Ansell, a global leader in protection ... Company of the Year Award. Ansell,s comprehensive product ... wide global footprint have placed it in a ... market. The Company,s established product line and robust ...
Breaking Medicine Technology: